Frontotemporal Dementia (FTD) upliFT-D (PBFT02) Clinical Trial
Information for people with FTD and their caregivers
upliFT-D trial key
- Name: upliFT-D
- Treatment: PBFT02
- Goal: Study the effectiveness and safety of a new gene therapy, PBFT02, in people with FTD caused by a GRN mutation
- Ages eligible: 35 to 75 years old
Passage Bio is studying a potential new therapy called PBFT02 for the treatment of frontotemporal dementia caused by a GRN mutation (FTD-GRN).
PBFT02 is a novel gene therapy intended to help replace the gene that doesn't work in people with FTD-GRN, called the GRN gene.
This clinical trial, called upliFT-D, is studying if PBFT02 can help people with FTD-GRN.
People between the ages of 35 and 75, diagnosed with FTD and a confirmed GRN mutation, will be included in this study. There are other criteria that determine eligibility, which may be discussed with a healthcare provider.
If you don't know if you have a GRN genetic mutation, click here for more information.
Contact Passage Bio to learn more:
We are here to help and we're happy to answer any questions you may have about FTD, the treatment we are studying, and the clinical trial.
Please fill out the form to the right below to contact Passage Bio. If you or your loved one is interested in participating in the study, please include the information listed below:
- Age
- Diagnosis
- Language preference
Clinical trial participation
Being a part of a clinical trial can feel overwhelming and lead to many questions. Hear from Chelsea Ortiz, a member of the Patient Engagement Team at Passage Bio, on how we can help support you and your loved ones throughout the clinical trial.
Passage Bio is a genetics medicine company focused on developing transforming therapies for central nervous system (CNS) disorders
One Commerce Square, 2005 Market Street, 39th Floor, Philadelphia, PA 19103 | PassageBio.com | © 2022 Passage Bio, Inc. All rights reserved. GLOBAL-FTD-2022-016
